A checklist for evaluating reports of expression profiling for treatment selection

Clinical Advances in Hematology and Oncology

Volumn 4, Issue 3, 2006, Pages 219-224

  Simon, Richard ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Biomarkers; Expression profiling; Pharmacogenomics; Predictive factors

Indexed keywords

ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; DNA;

ACCURACY; ARTICLE; CHECKLIST; CLINICAL TRIAL; CLUSTER ANALYSIS; DATA ANALYSIS; DISEASE ACTIVITY; DISEASE COURSE; DNA MICROARRAY; DRUG USE; FOOD AND DRUG ADMINISTRATION; GENE EXPRESSION PROFILING; HUMAN; INFORMATION PROCESSING; MALIGNANT NEOPLASTIC DISEASE; MATERIALS HANDLING; MEDICAL DECISION MAKING; MEDICAL SPECIALIST; MULTIVARIATE ANALYSIS; ONCOLOGY; OUTCOME ASSESSMENT; PATIENT CARE; PREDICTION; SAMPLE SIZE; SAMPLING; SAMPLING ERROR; UNITED STATES; VALIDATION STUDY;

GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; NEOPLASM PROTEINS; NEOPLASMS;

EID: 33745471507     PISSN: 15430790     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Gasparini G, Pozza F, Harris AL. Evaluating the potential usefulness of new prognostic and predictive indicators in node-negative breast cancer patients. J Natl Cancer Inst. 1993;85:1206-1219.
2. Hayes DF, Bast RC, Desch CE, et al. Tumor marker utility grading system: a framework to evaluate clinical utility of tumor markers. J Natl Cancer Inst. 1996;88:1456-1466.
3. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM. Reporting recommendations for tumor marker prognostic studies (REMARK). J Natl. Cancer Inst. 2005;97:1180-1184.
4. Simon RM, Korn EL, McShane LM, Radmacher MD, Wright GW, Zhao Y. Design and Analysis of DNA Microarray Investigations. New York: Springer; 2003.
5. Simon R. A roadmap for developing and validating therapeutically relevant genomic classifiers. J Clin Oncol. 2006;23:7332-7341.
6. Pusztai L, Hess KR. Clinical trial design for microarray predictive marker discovery and assessment. Ann Oncol. 2004;15:1731-1737.
7. Simon R. Development and validation of therapeutically relevant multi-gene biomarker classifiers. J Natl Cancer Inst. 2005;97:866-867.
8. Group BDW. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharm Therap. 2001;69:89-95.
9. Prentice RL. Surrogate endpoints in clinical trials: definition and operational criteria. Stat Med. 1989;8:431-440.
10. Dudoit S, Fridlyand J. Classification in microarray experiments. In: Speed T, ed. Statistical Analysis of Gene Expression Microarray Data. New York: Chapman & Hall/CRC; 2003:93-158.
11. Vasselli J, Shih JH, Iyengar SR, et al. Predicting survival in patients with metastatic kidney cancer by gene expression profiling in the primary tumor. Proc Natl. Acad Sci U S A. 2003;100:6958-6963.
12. Paik S, Shak S, Tang G, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med. 2004;351:2817-2826.
13. Simon R, Radmacher MD, Dobbin K, McShane LM. Pitfalls in the analysis of DNA microarray data: class prediction methods. J Nat Cancer Inst. 2003;95:14-18.
14. Simon R. Diagnostic and prognostic prediction using gene expression profiles in high dimensional microarray data. Br J Cancer. 2003;89:1599-1604.
15. Rosenwald A, Wright G, Chan WC, et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med. 2002;346:1937-1947.
16. Molinaro AM, Simon R, Pfeiffer RM. Prediction error estimation: a comparison of resampling methods. Bioinformatics. 2005;21:3301-3307.
17. Ambroise C, McLachlan GJ. Selection bias in gene extraction on the basis of microarray gene-expression data. Proc Natl Acad Sci. 2002;99:6562-66.
18. Dobbin K, Beer DG, Meyerson M, et al. Inter-laboratory comparability study of cancer gene expression analysis using oligonucleotide microarrays. Clin Cancer Res. 2005;11:565-572.
19. Hayes DF, Trock B, Harris AL. Assessing the clinical impact of prognostic factors: when is "statistically significant" clinically useful? Breast Cancer Res Treatment. 1998;52:305-319.
20. Simon R, Altman DG. Statistical aspects of prognostic factor studies in oncology. Br J Cancer. 1994;69:979-985.
21. Bast RC, Ravdin P, Hayes DF, et al. 2000 update of recommendations for the use of tumor markers in breast and colorectal cancer: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol. 2001; 19:1865-1878.
22. Simon R, Maitournam A. Evaluating the efficiency of targeted designs for randomized clinical trials. Clin Cancer Res. 2004; 10:6759-6763.
23. Maitournam A, Simon R. On the efficiency of targeted clinical trials. Stat Med. 2005;24:329-339.
24. Sargent DJ, Conley BA, Allegra C, Collette L. Clinical trial designs for predictive marker validation in cancer treatment trials. J Clin Oncol. 2005;23:2020-2027.
25. Simon R. When is a genomic classifier ready for prime time? Nat Clin Pract Oncol. 2004;1:2-3.
26. Kattan MW. Judging new markers by their ability to improve predictive accuracy. J Natl Cancer Inst. 2003;95:634-635.
27. Kattan MW. Evaluating a new marker's predictive contribution. Clin Cancer Res. 2004;10:822-824.
28. Dobbin K, Simon R. Sample size determination in microarray experiments for class comparison and prognostic classification. Biostatistics. 2005;6:27-38.
29. Radmacher MD, McShane LM, Simon R. A paradigm for class prediction using gene expression profiles. J Computational Biol. 2002;9:505-511.
30. Simon R. Targets for treatment success. Nat Clin Pract Oncol. 2005;3:1.